Since their introduction in 2011, immune checkpoint inhibitors (ICIs) have led to a paradigm shift in the field of cancer therapy. Originally approved by the US Food and Drug Administration for the treatment of advanced melanoma, the indications for use of ICIs now comprise an ever-expanding list of advanced malignancies, including non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, and urothelial carcinoma (1, 2) . Current agents target CTLA-4, as well as the programmed death 1 (PD-1) protein and its ligand, PD-L1, which negatively regulate T cell activation and T cell receptor signaling, respectively. By disinhibiting these regulatory pathways, ICIs overcome self tolerance and promote T cell-mediated expansion, resulting in robust anti-tumor immunity.
As a consequence of their mechanism of action, ICI therapy can induce autoimmune side effects affecting almost any organ system (3) . These are collectively referred to as immune-related adverse effects (IRAEs). The most common IRAEs are mild cutaneous or gastrointestinal symptoms. The rate of severe IRAEs with the use of a single ICI is lower than 2%, on average, among patients with advanced melanoma (1, 4) . However, less is known about IRAEs in patients with an underlying rheumatic disease. The CTLA-4 and PD-1 pathways have been implicated in the pathogenesis of various autoimmune diseases, and as such, these patients were excluded from the clinical trials that led to the approval of ICIs, because investigators were concerned about the potential induction of rheumatic disease flares with these therapies (1) .
There are only a limited number of reports focusing on ICI therapy in patients with underlying rheumatic disease. In 3 case series of patients with any autoimmune disease, including connective tissue diseases, psoriasis, thyroiditis, and inflammatory bowel disease, moderate-tosevere IRAEs were found to occur in 27-58% of the patients (5-7). Patients with inflammatory arthritis or connective tissue diseases have been suggested to have higher rates of IRAEs, although any conclusions are limited by the small number of patients studied (7, 8) . It is also unclear how often IRAEs in these patients represent either flares of their disease or new autoimmune events, and whether these events have any prognostic significance in terms of cancer survival.
PATIENTS AND METHODS
Institutional review board approval was obtained prior to initiating the study. All patients receiving either ipilimumab, nivolumab, pembrolizumab, or any combination thereof at Mayo Clinic in Rochester, Minnesota, regardless of their primary malignancy, were catalogued by the Mayo Clinic central pharmacy. A cohort of 700 patients received ICIs between January 1, 2011 and May 16, 2016. Patients with preexisting autoimmune rheumatic diseases were identified within this cohort, using a range of specific International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 codes. Of the 33 patients identified, 16 were included in the study based on a confirmed diagnosis of rheumatic disease according to the American College of Rheumatology criteria for these diseases, when such information was available.
For each patient, the entire inpatient and outpatient medical records from all providers at Mayo Clinic were reviewed. Baseline characteristics were collected along with relevant medical data. The oncologic history of each patient included staging, diagnosis, and molecular profile, along with the time course, response, and adverse effects of ICI therapy. The severity of IRAEs was graded based on the Common Terminology Criteria for Adverse Events (CTCAE; grading scale 0-5, ranging from grade 0 [no adverse event or within normal limits] to grade 5 [fatal adverse event]) (9) . Rheumatic diseases were characterized according to clinical characteristics, results of serologic testing, and treatments during and prior to ICI initiation. Diseases that lacked clear clinical diagnostic criteria were required to have a confirmatory tissue biopsy. These included idiopathic aortitis, sarcoidosis, and urticarial vasculitis.
Descriptive statistics were used to summarize the characteristics of the cohort. Continuous and categorical variables were presented using percentages and medians. P values less than or equal to 0.05 were considered significant. Analyses were formed using Microsoft Excel 2010.
RESULTS
The baseline characteristics of the 16 patients identified are presented in Table 1 . The median age was 68.3 years and 81% of patients were female. The most common rheumatic diseases were rheumatoid arthritis (n = 5) and polymyalgia rheumatica (n = 5). Four patients had 2 comorbid rheumatic diseases, which are each listed separately in Table 1 . Ten patients (63%) had previously received a disease-modifying antirheumatic drug (DMARD), but only 2 of the patients were still taking this DMARD at the time of ICI initiation. Three additional patients were receiving glucocorticoids at the time of ICI initiation. Standardized disease activity scores were not available for any patient at baseline.
Fifteen patients (94%) had metastatic or stage IV cancer and had previously received chemotherapy prior to starting an ICI. The 1 patient without metastatic or stage IV disease had stage II non-Hodgkin's lymphoma. The most common cancer was malignant melanoma (n = 10), followed by pulmonary malignancies (n = 4) and non-Hodgkin's lymphoma (n = 2).
All patients received their immunotherapy as standard care, and none were participating in a clinical trial related to their malignancy or rheumatic disease. Six patients (38%) had IRAEs (as described in Table 2 ). These were all diagnosed on the basis of clinical symptoms, except in the case of interstitial pneumonitis and cases of colitis, for which a biopsy was performed. Colitis was the most common manifestation (n = 3), and only 1 patient exhibited a flare of their rheumatic disease. This Of note, as shown in Figure 1 , in this small cohort of patients, those who experienced IRAEs tended to survive longer than those who did not have an IRAE (median duration of survival 17 months versus 1.4 months, respectively; P = 0.003). Five of the 6 patients with an IRAE were still alive at the time of analysis, compared to only 1 patient in the group without IRAEs. There were no significant differences between groups with regard to age, sex, duration of prior rheumatic disease, time from cancer diagnosis to ICI therapy, or duration of ICI therapy. The ICI regimens received in the IRAE group (Table 2) did not vary significantly from those received by the rest of the cohort.
A greater proportion of patients with an IRAE had melanoma compared to those without an IRAE (83% versus 50%), but this difference did not reach statistical significance (P = 0.31). The difference in survival remained statistically significant when analyzing only patients with melanoma (P = 0.01). The average time from cancer diagnosis to initiation of ICI therapy for the whole study group was 28 months. For every patient who died after receiving an ICI, the underlying malignancy was listed to be the primary cause of death.
DISCUSSION
Cancer immunotherapy remains a challenge in patients with rheumatic diseases. The initial clinical trials of ICIs excluded patients with autoimmune diseases, and clinicians may hesitate to offer these drugs given the concern for inducing a disease flare. This study adds further support to the emerging notion that the rate of IRAEs is not necessarily higher in this group compared to the general population. Of our cohort of 16 patients, only 6 (38%) had an IRAE or flare of their rheumatic disease. Of these events, 2 were graded as mild, and all 6 patients responded well to glucocorticoids. This is consistent with what is currently known about the management of IRAEs (2,10). Furthermore, we found no association between DMARD use, either before or during ICI therapy, and the risk of development of an IRAE. We were unable to directly assess the impact of rheumatic disease activity on survival or IRAE risk. 
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Previous case series that included patients with any autoimmune disease demonstrated slightly higher rates of IRAEs than were observed in the present cohort. The largest series to date included 30 patients, of whom 50% had an IRAE, with just over one-half of these patients showing symptoms of a disease flare (5) . A second series showed a rate of IRAEs of 67%, of which 38% were disease flares (7). The lower rates observed in our study could be attributable to the high percentage of patients who were receiving immunotherapy late in their disease course. In our study, 63% of the patients died within 6 months of discontinuing an ICI, which may have prevented recognition of IRAEs that manifested as mild symptoms or that would have occurred later in the treatment course. The latter possibility is supported by autopsy observations of profound lymphocytic inflammation previously found to be present in several organs in asymptomatic patients receiving ICI therapy (11) . There could also be a dose effect, as several patients received only 1 or 2 ICI treatments prior to discontinuation.
Our finding of increased overall survival in patients with an IRAE is limited by the small number of patients studied and the heterogeneity of their treatments and underlying malignancy. The clinical trials investigating ICIs have not clearly identified this trend in the general population, although the results of 2 retrospective studies suggested that the development of IRAEs is positively associated with clinical outcomes (12, 13) . Mechanistically, it is reasonable to theorize that patients with robust immune responses are more likely to respond to immunotherapy and present with IRAEs. The proinflammatory cytokine interleukin-17 (IL-17) has been associated with a higher risk of IRAEs, while IL-10 is associated with higher rates of cancer relapse (14) . Furthermore, combined immunotherapy regimens have been associated with improved overall survival compared to monotherapy, and patients treated with combination immunotherapy present with higher rates of IRAEs, suggesting that there is a potential correlation between the presence of an IRAE and treatment efficacy (1, 15) .
While patients with rheumatic disease can experience IRAEs and disease flares, this study further suggests that routinely withholding ICI therapy in these patients is unfounded. The rates of IRAEs in the general population are as high as 70-90%, with 10-20% of these being severe manifestations (11) . This is comparable to the rates reported in studies on patients with autoimmune disease, and higher than what is reported herein. In addition, trials that investigated switching ICIs after treatment failure showed that patients with an IRAE while receiving one drug were not necessarily predisposed to IRAEs while receiving a second drug (16) . There was 1 such patient in this study, an individual who showed treatment tolerance for pembrolizumab well after being treated for ipilimumab-induced colitis.
Our study is limited by its retrospective nature and also by the small sample size of the cohort. This limited cohort size is likely explained by 2 major factors. First, IRAEs are likely vastly underreported, in part owing to the current system for adverse event reporting (the CTCAE) in oncology trials, which might not have the granularity needed to assess for flares of rheumatic disease. Second, there is reluctance to expose patients with autoimmune disease to ICIs, and indeed, our data suggest that the presence of a comorbid rheumatic disease was a factor in delaying immunotherapy. Specifically, in our cohort, 94% of patients received ICI therapy only after having failed other conventional chemotherapeutic regimens, despite the fact that ICIs were on the market and approved for their clinical indication. In addition, the patients identified in our study were in advanced stages of their malignancies upon initiation of ICI therapy. This may limit the generalizability of our findings, as ICI treatments are now often used as first-line agents for many advanced malignancies.
The patients identified in this study had a heterogeneous group of comorbid rheumatic diseases and malignancies. The type and severity of each rheumatic disease may play an important role in the risk of both occurrence of flare of underlying disease and IRAEs. We were unable to directly assess disease activity due to a lack of reporting of standardized measures; however, only 2 patients in our cohort were being treated with a DMARD at the time of ICI therapy. This suggests that many patients were in drug-free remission or had relatively mild disease. Further large, prospective studies are needed to address the link between the type, severity, and concurrent activity of the rheumatic disease and the risk of flare and IRAEs. It is possible that patients with more severe or active disease are at higher risk of developing these complications.
Comorbid rheumatic disease poses a major challenge in the rapidly expanding field of cancer immunotherapy. Although these patients do not appear to have a significantly increased incidence or severity of adverse effects, treatment decisions must factor in the clinical judgment. Some studies have proposed assessment of predictive biomarkers, pretreatment evaluations, and biologic monitoring in such patients, although, at present, these suggestions rely on a relatively small body of evidence (11) . Larger, prospective studies will be necessary to validate these findings and establish evidence-based guidelines for appropriate identification and rating of the rheumatic disease IRAEs as well as their treatment, such that patients can continue to receive potentially life-saving cancer treatments.
